WeVote
Log In

Bill

Bill

H 1325

An Act to ensure access to generic medication

194th Legislature (2025-2026) Introduced by Alan Silvia

Legislation requiring insurers and pharmacies to improve access to lower-cost generic medications, reducing out-of-pocket costs for Massachusetts residents.

Accompanied a study order, see H4789
0
WeVote Research Nonpartisan
Bill Summary · H 1325

Legislative bill overview

H 1325 aims to improve access to generic medications in Massachusetts by removing or reducing barriers to their use and affordability. The bill addresses pharmaceutical costs and medication accessibility through measures that likely involve insurance coverage requirements, pharmacy dispensing rules, or pricing transparency for generic drugs.

Why is this important

Generic medications cost significantly less than brand-name equivalents while containing identical active ingredients, yet access barriers—such as insurance plan restrictions or pharmacy substitution limitations—prevent many Massachusetts residents from using them. Expanding generic access could reduce healthcare costs for individuals and the state while improving medication adherence among lower-income populations.

Potential points of contention

  • Insurance industry concerns: Insurers may oppose requirements that expand generic coverage or reduce cost-sharing, arguing it increases their expenses
  • Brand-name pharmaceutical opposition: Drug manufacturers may resist measures that accelerate generic substitution, potentially impacting their market share and profitability
  • Implementation costs: Healthcare providers and pharmacies may face administrative or infrastructure expenses to comply with new access requirements, raising questions about who bears these costs

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.